沙美特罗/氟替卡松治疗哮喘的临床研究  

Clinical study of salmeterol/fluticasone on asthma

作　　者：迟春花[1] 陈建[1] 李小玲[1] 魏淑敏[1] 何冰[1] 王广发[1] 

机构地区：[1]北京大学第一医院呼吸科,北京100034

出　　处：《临床荟萃》2006年第14期997-999,共3页Clinical Focus

摘　　要：目的 比较沙美特罗/氟替卡松复方制剂舒利迭（SFC）与单用吸入糖皮质激素（ICS）治疗哮喘的疗效.方法 88例中重度哮喘患者分为两组：①SFC组（57例）使用SFC 50/100 μg 或50/250 μg,吸入,每日2次,治疗4周;②ICS组（31例）,每日200～500 μg 氟替卡松或等价药物,每日2次,治疗4周. 观察哮喘症状评分、夜间憋醒次数、缓解药物使用次数、症状缓解时间及最大呼气流速（PEF）的变化.结果 治疗前SFC组患者日间症状评分及夜间憋醒次数均较ICS组重（均P〈0.05）;治疗后SFC组平均症状缓解时间为3天,而ICS组为9天（P〈0.001）.治疗4周SFC组哮喘日间症状评分减少2分,ICS组减少1分（P〈0.05）,夜间憋醒次数两组分别减少1次、0次（P〈0.05）;治疗4周肺功能有效率SFC组和ICS组分别为70.8%、45.8%（P〈0.05）;缓解药物使用次数两组差别无统计学意义;两组耐受性均较好,不良反应发生率均较低.结论 改善中重度哮喘患者的症状及肺功能,SFC相比于单用ICS,更快、更有效.Objective To compare the efficacy of salmeterol/fluticasone propionate seretide（SFC） with inhaled corticosteroids （ICS） in asthmatics. Methods Eighty-eight moderate-to-severe asthmatics were divided into two treatment groups： （1） SFC group （ n =57）： Seretide 50/100μg or 50/250μg twice daily for four weeks and （2） ICS group （ n =31） ： 100 μg to 250 μg fluticasone propionate or equivalent twice daily for four weeks. Symptom scores, night awakening time, reliever use, symptom alleviating time and morning peak expiratory flow （PEF） were evaluated. Results Asthma symptom scores and night awakening time were more severe in SFC group than in ICS group before treatment（all P 〈0.05）. After treatment the mean time of symptom alleviating was three days in SFC group and nine days in ICS group（ P 〈0. 001）. The asthma symptom scores decreased 2 in SFC group and 1 in ICS group at four week after treatment（ P 〈0.05）. The night awakening time reduced 1 in SFC group and 0 in ICS group at week four（ P〈0.05）. At week four, the pulmonary function efficacy was 70.8% in SFC group and 45.8% in ICS group（ P 〈0.05）. There was no significant difference for the reliever use between the two groups. Both treatments were well tolerated, with a similar low incidence of adverse events. Conclusion SFC got improvement in symptom control and pulmonary function more quickly and was more effective than ICS alone on moderate-to-severe asthma.

关 键 词：哮喘 糖皮质激素 Β2受体激动剂 

分 类 号：R562.2[医药卫生—呼吸系统]